{"title":"Clinical characteristics and risk factors analysis of <i>Clostridioides difficile</i> infection in ulcerative colitis patients during biologic therapy.","authors":"Tingting Xu, Ying Xie","doi":"10.3389/fcimb.2026.1803104","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the risk factors for <i>Clostridioides difficile</i> infection (CDI) in patients with ulcerative colitis (UC) during biologic therapy.</p><p><strong>Methods: </strong>Patients diagnosed with UC who received Infliximab (IFX) or Vedolizumab (VDZ) were enrolled. Their clinical characteristics and risk factors for CDI were analyzed.</p><p><strong>Results: </strong>A total of 110 UC patients treated with IFX (61 cases) or VDZ (49 cases) were included. The overall positive rate of <i>Clostridioides difficile</i> (<i>C. difficile</i>) was 28.2%. Positive Epstein-Barr virus (EBV)-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients receiving IFX/VDZ therapy. The incidence of CDI was the highest within 0-3 months after IFX/VDZ treatment.</p><p><strong>Conclusion: </strong>Positive EBV-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients during IFX/VDZ therapy.</p>","PeriodicalId":12458,"journal":{"name":"Frontiers in Cellular and Infection Microbiology","volume":"16 ","pages":"1803104"},"PeriodicalIF":4.8000,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13066211/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cellular and Infection Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcimb.2026.1803104","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the risk factors for Clostridioides difficile infection (CDI) in patients with ulcerative colitis (UC) during biologic therapy.
Methods: Patients diagnosed with UC who received Infliximab (IFX) or Vedolizumab (VDZ) were enrolled. Their clinical characteristics and risk factors for CDI were analyzed.
Results: A total of 110 UC patients treated with IFX (61 cases) or VDZ (49 cases) were included. The overall positive rate of Clostridioides difficile (C. difficile) was 28.2%. Positive Epstein-Barr virus (EBV)-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients receiving IFX/VDZ therapy. The incidence of CDI was the highest within 0-3 months after IFX/VDZ treatment.
Conclusion: Positive EBV-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients during IFX/VDZ therapy.
期刊介绍：
Frontiers in Cellular and Infection Microbiology is a leading specialty journal, publishing rigorously peer-reviewed research across all pathogenic microorganisms and their interaction with their hosts. Chief Editor Yousef Abu Kwaik, University of Louisville is supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
Frontiers in Cellular and Infection Microbiology includes research on bacteria, fungi, parasites, viruses, endosymbionts, prions and all microbial pathogens as well as the microbiota and its effect on health and disease in various hosts. The research approaches include molecular microbiology, cellular microbiology, gene regulation, proteomics, signal transduction, pathogenic evolution, genomics, structural biology, and virulence factors as well as model hosts. Areas of research to counteract infectious agents by the host include the host innate and adaptive immune responses as well as metabolic restrictions to various pathogenic microorganisms, vaccine design and development against various pathogenic microorganisms, and the mechanisms of antibiotic resistance and its countermeasures.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
